$14.670
-0.236 (-1.61%)At close
FDMT News
FDMT Events
4DMT Reports Q2 Revenue of $3.78M, Beating Consensus
Reports Q2 revenue $3.78M, consensus $2.71M. "The second quarter of 2026 reflected continued strong execution across 4DMT, including completion of enrollment for 4FRONT-2, presenting positive long-term PRISM data and strengthening our financial flexibility through securing a strategic credit facility with Hercules," said David Kirn, Co-founder, President and Chief Executive Officer of 4DMT. "With topline data from both 4FRONT-1 and 4FRONT-2 in wet AMD expected in 2027, our DME Phase 3 expected to initiate in the third quarter and our Investor Day planned in October, we are well positioned to advance 4D-150 as a potential paradigm-changing backbone therapy for patients with wet AMD and DME."
4D Molecular Completes Enrollment for 4FRONT-2 Trial
4D Molecular announced enrollment completion for 4FRONT-2, the second Phase 3 clinical trial in our global program, evaluating 4D-150 in patients with wet age-related macular degeneration.
4DMT Reports Q1 Revenue of $3.05M, Beating Consensus
Reports Q1 revenue $3.05M, consensus $2.59M. "We started 2026 with strong execution, completing enrollment in 4FRONT-1 ahead of schedule reflecting strong investigator and patient enthusiasm for 4D-150," said David Kirn, Co-founder, President and Chief Executive Officer of 4DMT. "For the remainder of the year, we look forward to completing 4FRONT-2 enrollment, initiating our global Phase 3 clinical trial in DME, and sharing 2-year data from PRISM and SPECTRA."
4D Molecular Files $400M Mixed Securities Shelf
4D Molecular files $400M mixed securities shelf
4D Molecular Therapeutics Completes Enrollment for 4FRONT-1 Clinical Trial
4D Molecular Therapeutics announced enrollment completion for 4FRONT-1, the first Phase 3 clinical trial evaluating 4D-150 in patients with wet age-related macular degeneration. 4FRONT-1 is a Phase 3 multicenter, randomized, double-masked, aflibercept 2 mg comparator-controlled study of intravitreal 4D-150 in wet AMD. The primary endpoint is non-inferiority in the mean change from baseline in best corrected visual acuity at 52 weeks. The key secondary endpoint is treatment burden reduction comparing the number of aflibercept injections received in the 4D-150 arm versus the aflibercept comparator arm over 52 weeks. Patients in both arms will be eligible for supplemental aflibercept injections. 4FRONT-1 is evaluating treatment-naive wet AMD patients at sites in North America. Topline primary endpoint data from 4FRONT-1 is expected in H1 2027. The second Phase 3 for wet AMD, 4FRONT-2, is a global trial with an identical design to 4FRONT-1 except for enrolling both treatment-naive and recently diagnosed treatment-experienced wet AMD patients. 4FRONT-2 is expected to complete enrollment in H2 2026 with topline primary endpoint data expected in H2 2027.
This page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.